Global Plasma Protein Therapeutics

Plasma Protein Therapeutics Comprehensive Study by Type (Immunoglobulin, Albumin, Plasma-derived factor VIII, Plasma Proteins, Globulins, Fibrinogen), Application (Hemophilia, Idiopathic thrombocytopenic purpura, Primary immunodeficiency disorder, Others), End Users (Hospitals, Others) Players and Region - Global Market Outlook to 2028

Plasma Protein Therapeutics Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Plasma Protein Therapeutics Market Overview:
Plasma protein therapeutics are a class of drugs made from proteins found in human plasma. These proteins have a variety of biological functions, including regulating blood clotting, immune responses, and maintaining body fluid balance. Plasma protein therapeutics are used to treat a wide range of medical conditions including bleeding disorders, immune deficiencies, and genetic disorders. They are often administered by injection or infusion and require careful monitoring to ensure proper dosing and minimize potential side effects. The rise in research and development activities for plasma protein therapeutics drive the growth of the plasma protein therapeutics market.

AttributesDetails
Study Period2018-2028
Base Year2022
Forecast Period2023-2028
Historical Period2018-2022
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Influencing Trend:
Increased Research and Development Activities for Plasma Protein Therapeutics

Market Growth Drivers:
Increased Incidence of Autoimmune Diseases and Increasing Adoption of Different Strategies by Key Market Players

Challenges:
Raising Awareness of the Importance of Blood Donation and Encouraging New and Regular Blood Donation Habits.

Restraints:
Stringent Regulations for Handling Plasma Protein Products and Lack of Proper Reimbursement Policies.

Opportunities:
Increasing Government Initiatives, Escalating Awareness Levels Among Blood Donors and Increased Research Partnerships

Competitive Landscape:

Some of the key players profiled in the report are Octapharma AG (Switzerland), CSL Limited (Australia), ADMA Biologics Inc. (United States), Taibang Biological Group Co. Ltd (China), Bayer AG (Germany), Bio Products Laboratory Ltd. (United Kingdom), Takeda Pharmaceutical Company Limited (Japan), Grifols (Spain), Kedrion (Italy) and Baxter International Inc. (United States). Considering Market by End Users, the sub-segment i.e. Hospitals will boost the Plasma Protein Therapeutics market.

Latest Market Insights:
In November 2019, ADMA Biologics, Inc., a commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficiency patients at risk of infection and prevention of certain infectious diseases, was admitted to membership. Plasma Protein Therapeutics Association (PPTA).

In January 2022, Octapharma will expand indications in the European Union (EU) for cutaquig, a human immunoglobulin for subcutaneous administration, providing more flexible treatment options for patients with a much wider range of acquired immunodeficiency.

What Can be Explored with the Plasma Protein Therapeutics Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Plasma Protein Therapeutics Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Plasma Protein Therapeutics
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Plasma Protein Therapeutics market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Plasma Protein Therapeutics market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Immunoglobulin
  • Albumin
  • Plasma-derived factor VIII
  • Plasma Proteins
  • Globulins
  • Fibrinogen
By Application
  • Hemophilia
  • Idiopathic thrombocytopenic purpura
  • Primary immunodeficiency disorder
  • Others
By End Users
  • Hospitals
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Incidence of Autoimmune Diseases
      • 3.2.2. Increasing Adoption of Different Strategies by Key Market Players
    • 3.3. Market Challenges
      • 3.3.1. Raising Awareness of the Importance of Blood Donation and Encouraging New and Regular Blood Donation Habits.
    • 3.4. Market Trends
      • 3.4.1. Increased Research and Development Activities for Plasma Protein Therapeutics
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Plasma Protein Therapeutics, by Type, Application, End Users and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Plasma Protein Therapeutics (Value)
      • 5.2.1. Global Plasma Protein Therapeutics by: Type (Value)
        • 5.2.1.1. Immunoglobulin
        • 5.2.1.2. Albumin
        • 5.2.1.3. Plasma-derived factor VIII
        • 5.2.1.4. Plasma Proteins
        • 5.2.1.5. Globulins
        • 5.2.1.6. Fibrinogen
      • 5.2.2. Global Plasma Protein Therapeutics by: Application (Value)
        • 5.2.2.1. Hemophilia
        • 5.2.2.2. Idiopathic thrombocytopenic purpura
        • 5.2.2.3. Primary immunodeficiency disorder
        • 5.2.2.4. Others
      • 5.2.3. Global Plasma Protein Therapeutics by: End Users (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Others
      • 5.2.4. Global Plasma Protein Therapeutics Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Plasma Protein Therapeutics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Octapharma AG (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. CSL Limited (Australia)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. ADMA Biologics Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Taibang Biological Group Co. Ltd (China)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Bayer AG (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Bio Products Laboratory Ltd. (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Takeda Pharmaceutical Company Limited (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Grifols (Spain)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Kedrion (Italy)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Baxter International Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Plasma Protein Therapeutics Sale, by Type, Application, End Users and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Plasma Protein Therapeutics (Value)
      • 7.2.1. Global Plasma Protein Therapeutics by: Type (Value)
        • 7.2.1.1. Immunoglobulin
        • 7.2.1.2. Albumin
        • 7.2.1.3. Plasma-derived factor VIII
        • 7.2.1.4. Plasma Proteins
        • 7.2.1.5. Globulins
        • 7.2.1.6. Fibrinogen
      • 7.2.2. Global Plasma Protein Therapeutics by: Application (Value)
        • 7.2.2.1. Hemophilia
        • 7.2.2.2. Idiopathic thrombocytopenic purpura
        • 7.2.2.3. Primary immunodeficiency disorder
        • 7.2.2.4. Others
      • 7.2.3. Global Plasma Protein Therapeutics by: End Users (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Others
      • 7.2.4. Global Plasma Protein Therapeutics Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Plasma Protein Therapeutics: by Type(USD Million)
  • Table 2. Plasma Protein Therapeutics Immunoglobulin , by Region USD Million (2017-2022)
  • Table 3. Plasma Protein Therapeutics Albumin , by Region USD Million (2017-2022)
  • Table 4. Plasma Protein Therapeutics Plasma-derived factor VIII , by Region USD Million (2017-2022)
  • Table 5. Plasma Protein Therapeutics Plasma Proteins , by Region USD Million (2017-2022)
  • Table 6. Plasma Protein Therapeutics Globulins , by Region USD Million (2017-2022)
  • Table 7. Plasma Protein Therapeutics Fibrinogen , by Region USD Million (2017-2022)
  • Table 8. Plasma Protein Therapeutics: by Application(USD Million)
  • Table 9. Plasma Protein Therapeutics Hemophilia , by Region USD Million (2017-2022)
  • Table 10. Plasma Protein Therapeutics Idiopathic thrombocytopenic purpura , by Region USD Million (2017-2022)
  • Table 11. Plasma Protein Therapeutics Primary immunodeficiency disorder , by Region USD Million (2017-2022)
  • Table 12. Plasma Protein Therapeutics Others , by Region USD Million (2017-2022)
  • Table 13. Plasma Protein Therapeutics: by End Users(USD Million)
  • Table 14. Plasma Protein Therapeutics Hospitals , by Region USD Million (2017-2022)
  • Table 15. Plasma Protein Therapeutics Others , by Region USD Million (2017-2022)
  • Table 16. South America Plasma Protein Therapeutics, by Country USD Million (2017-2022)
  • Table 17. South America Plasma Protein Therapeutics, by Type USD Million (2017-2022)
  • Table 18. South America Plasma Protein Therapeutics, by Application USD Million (2017-2022)
  • Table 19. South America Plasma Protein Therapeutics, by End Users USD Million (2017-2022)
  • Table 20. Brazil Plasma Protein Therapeutics, by Type USD Million (2017-2022)
  • Table 21. Brazil Plasma Protein Therapeutics, by Application USD Million (2017-2022)
  • Table 22. Brazil Plasma Protein Therapeutics, by End Users USD Million (2017-2022)
  • Table 23. Argentina Plasma Protein Therapeutics, by Type USD Million (2017-2022)
  • Table 24. Argentina Plasma Protein Therapeutics, by Application USD Million (2017-2022)
  • Table 25. Argentina Plasma Protein Therapeutics, by End Users USD Million (2017-2022)
  • Table 26. Rest of South America Plasma Protein Therapeutics, by Type USD Million (2017-2022)
  • Table 27. Rest of South America Plasma Protein Therapeutics, by Application USD Million (2017-2022)
  • Table 28. Rest of South America Plasma Protein Therapeutics, by End Users USD Million (2017-2022)
  • Table 29. Asia Pacific Plasma Protein Therapeutics, by Country USD Million (2017-2022)
  • Table 30. Asia Pacific Plasma Protein Therapeutics, by Type USD Million (2017-2022)
  • Table 31. Asia Pacific Plasma Protein Therapeutics, by Application USD Million (2017-2022)
  • Table 32. Asia Pacific Plasma Protein Therapeutics, by End Users USD Million (2017-2022)
  • Table 33. China Plasma Protein Therapeutics, by Type USD Million (2017-2022)
  • Table 34. China Plasma Protein Therapeutics, by Application USD Million (2017-2022)
  • Table 35. China Plasma Protein Therapeutics, by End Users USD Million (2017-2022)
  • Table 36. Japan Plasma Protein Therapeutics, by Type USD Million (2017-2022)
  • Table 37. Japan Plasma Protein Therapeutics, by Application USD Million (2017-2022)
  • Table 38. Japan Plasma Protein Therapeutics, by End Users USD Million (2017-2022)
  • Table 39. India Plasma Protein Therapeutics, by Type USD Million (2017-2022)
  • Table 40. India Plasma Protein Therapeutics, by Application USD Million (2017-2022)
  • Table 41. India Plasma Protein Therapeutics, by End Users USD Million (2017-2022)
  • Table 42. South Korea Plasma Protein Therapeutics, by Type USD Million (2017-2022)
  • Table 43. South Korea Plasma Protein Therapeutics, by Application USD Million (2017-2022)
  • Table 44. South Korea Plasma Protein Therapeutics, by End Users USD Million (2017-2022)
  • Table 45. Taiwan Plasma Protein Therapeutics, by Type USD Million (2017-2022)
  • Table 46. Taiwan Plasma Protein Therapeutics, by Application USD Million (2017-2022)
  • Table 47. Taiwan Plasma Protein Therapeutics, by End Users USD Million (2017-2022)
  • Table 48. Australia Plasma Protein Therapeutics, by Type USD Million (2017-2022)
  • Table 49. Australia Plasma Protein Therapeutics, by Application USD Million (2017-2022)
  • Table 50. Australia Plasma Protein Therapeutics, by End Users USD Million (2017-2022)
  • Table 51. Rest of Asia-Pacific Plasma Protein Therapeutics, by Type USD Million (2017-2022)
  • Table 52. Rest of Asia-Pacific Plasma Protein Therapeutics, by Application USD Million (2017-2022)
  • Table 53. Rest of Asia-Pacific Plasma Protein Therapeutics, by End Users USD Million (2017-2022)
  • Table 54. Europe Plasma Protein Therapeutics, by Country USD Million (2017-2022)
  • Table 55. Europe Plasma Protein Therapeutics, by Type USD Million (2017-2022)
  • Table 56. Europe Plasma Protein Therapeutics, by Application USD Million (2017-2022)
  • Table 57. Europe Plasma Protein Therapeutics, by End Users USD Million (2017-2022)
  • Table 58. Germany Plasma Protein Therapeutics, by Type USD Million (2017-2022)
  • Table 59. Germany Plasma Protein Therapeutics, by Application USD Million (2017-2022)
  • Table 60. Germany Plasma Protein Therapeutics, by End Users USD Million (2017-2022)
  • Table 61. France Plasma Protein Therapeutics, by Type USD Million (2017-2022)
  • Table 62. France Plasma Protein Therapeutics, by Application USD Million (2017-2022)
  • Table 63. France Plasma Protein Therapeutics, by End Users USD Million (2017-2022)
  • Table 64. Italy Plasma Protein Therapeutics, by Type USD Million (2017-2022)
  • Table 65. Italy Plasma Protein Therapeutics, by Application USD Million (2017-2022)
  • Table 66. Italy Plasma Protein Therapeutics, by End Users USD Million (2017-2022)
  • Table 67. United Kingdom Plasma Protein Therapeutics, by Type USD Million (2017-2022)
  • Table 68. United Kingdom Plasma Protein Therapeutics, by Application USD Million (2017-2022)
  • Table 69. United Kingdom Plasma Protein Therapeutics, by End Users USD Million (2017-2022)
  • Table 70. Netherlands Plasma Protein Therapeutics, by Type USD Million (2017-2022)
  • Table 71. Netherlands Plasma Protein Therapeutics, by Application USD Million (2017-2022)
  • Table 72. Netherlands Plasma Protein Therapeutics, by End Users USD Million (2017-2022)
  • Table 73. Rest of Europe Plasma Protein Therapeutics, by Type USD Million (2017-2022)
  • Table 74. Rest of Europe Plasma Protein Therapeutics, by Application USD Million (2017-2022)
  • Table 75. Rest of Europe Plasma Protein Therapeutics, by End Users USD Million (2017-2022)
  • Table 76. MEA Plasma Protein Therapeutics, by Country USD Million (2017-2022)
  • Table 77. MEA Plasma Protein Therapeutics, by Type USD Million (2017-2022)
  • Table 78. MEA Plasma Protein Therapeutics, by Application USD Million (2017-2022)
  • Table 79. MEA Plasma Protein Therapeutics, by End Users USD Million (2017-2022)
  • Table 80. Middle East Plasma Protein Therapeutics, by Type USD Million (2017-2022)
  • Table 81. Middle East Plasma Protein Therapeutics, by Application USD Million (2017-2022)
  • Table 82. Middle East Plasma Protein Therapeutics, by End Users USD Million (2017-2022)
  • Table 83. Africa Plasma Protein Therapeutics, by Type USD Million (2017-2022)
  • Table 84. Africa Plasma Protein Therapeutics, by Application USD Million (2017-2022)
  • Table 85. Africa Plasma Protein Therapeutics, by End Users USD Million (2017-2022)
  • Table 86. North America Plasma Protein Therapeutics, by Country USD Million (2017-2022)
  • Table 87. North America Plasma Protein Therapeutics, by Type USD Million (2017-2022)
  • Table 88. North America Plasma Protein Therapeutics, by Application USD Million (2017-2022)
  • Table 89. North America Plasma Protein Therapeutics, by End Users USD Million (2017-2022)
  • Table 90. United States Plasma Protein Therapeutics, by Type USD Million (2017-2022)
  • Table 91. United States Plasma Protein Therapeutics, by Application USD Million (2017-2022)
  • Table 92. United States Plasma Protein Therapeutics, by End Users USD Million (2017-2022)
  • Table 93. Canada Plasma Protein Therapeutics, by Type USD Million (2017-2022)
  • Table 94. Canada Plasma Protein Therapeutics, by Application USD Million (2017-2022)
  • Table 95. Canada Plasma Protein Therapeutics, by End Users USD Million (2017-2022)
  • Table 96. Mexico Plasma Protein Therapeutics, by Type USD Million (2017-2022)
  • Table 97. Mexico Plasma Protein Therapeutics, by Application USD Million (2017-2022)
  • Table 98. Mexico Plasma Protein Therapeutics, by End Users USD Million (2017-2022)
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Plasma Protein Therapeutics: by Type(USD Million)
  • Table 110. Plasma Protein Therapeutics Immunoglobulin , by Region USD Million (2023-2028)
  • Table 111. Plasma Protein Therapeutics Albumin , by Region USD Million (2023-2028)
  • Table 112. Plasma Protein Therapeutics Plasma-derived factor VIII , by Region USD Million (2023-2028)
  • Table 113. Plasma Protein Therapeutics Plasma Proteins , by Region USD Million (2023-2028)
  • Table 114. Plasma Protein Therapeutics Globulins , by Region USD Million (2023-2028)
  • Table 115. Plasma Protein Therapeutics Fibrinogen , by Region USD Million (2023-2028)
  • Table 116. Plasma Protein Therapeutics: by Application(USD Million)
  • Table 117. Plasma Protein Therapeutics Hemophilia , by Region USD Million (2023-2028)
  • Table 118. Plasma Protein Therapeutics Idiopathic thrombocytopenic purpura , by Region USD Million (2023-2028)
  • Table 119. Plasma Protein Therapeutics Primary immunodeficiency disorder , by Region USD Million (2023-2028)
  • Table 120. Plasma Protein Therapeutics Others , by Region USD Million (2023-2028)
  • Table 121. Plasma Protein Therapeutics: by End Users(USD Million)
  • Table 122. Plasma Protein Therapeutics Hospitals , by Region USD Million (2023-2028)
  • Table 123. Plasma Protein Therapeutics Others , by Region USD Million (2023-2028)
  • Table 124. South America Plasma Protein Therapeutics, by Country USD Million (2023-2028)
  • Table 125. South America Plasma Protein Therapeutics, by Type USD Million (2023-2028)
  • Table 126. South America Plasma Protein Therapeutics, by Application USD Million (2023-2028)
  • Table 127. South America Plasma Protein Therapeutics, by End Users USD Million (2023-2028)
  • Table 128. Brazil Plasma Protein Therapeutics, by Type USD Million (2023-2028)
  • Table 129. Brazil Plasma Protein Therapeutics, by Application USD Million (2023-2028)
  • Table 130. Brazil Plasma Protein Therapeutics, by End Users USD Million (2023-2028)
  • Table 131. Argentina Plasma Protein Therapeutics, by Type USD Million (2023-2028)
  • Table 132. Argentina Plasma Protein Therapeutics, by Application USD Million (2023-2028)
  • Table 133. Argentina Plasma Protein Therapeutics, by End Users USD Million (2023-2028)
  • Table 134. Rest of South America Plasma Protein Therapeutics, by Type USD Million (2023-2028)
  • Table 135. Rest of South America Plasma Protein Therapeutics, by Application USD Million (2023-2028)
  • Table 136. Rest of South America Plasma Protein Therapeutics, by End Users USD Million (2023-2028)
  • Table 137. Asia Pacific Plasma Protein Therapeutics, by Country USD Million (2023-2028)
  • Table 138. Asia Pacific Plasma Protein Therapeutics, by Type USD Million (2023-2028)
  • Table 139. Asia Pacific Plasma Protein Therapeutics, by Application USD Million (2023-2028)
  • Table 140. Asia Pacific Plasma Protein Therapeutics, by End Users USD Million (2023-2028)
  • Table 141. China Plasma Protein Therapeutics, by Type USD Million (2023-2028)
  • Table 142. China Plasma Protein Therapeutics, by Application USD Million (2023-2028)
  • Table 143. China Plasma Protein Therapeutics, by End Users USD Million (2023-2028)
  • Table 144. Japan Plasma Protein Therapeutics, by Type USD Million (2023-2028)
  • Table 145. Japan Plasma Protein Therapeutics, by Application USD Million (2023-2028)
  • Table 146. Japan Plasma Protein Therapeutics, by End Users USD Million (2023-2028)
  • Table 147. India Plasma Protein Therapeutics, by Type USD Million (2023-2028)
  • Table 148. India Plasma Protein Therapeutics, by Application USD Million (2023-2028)
  • Table 149. India Plasma Protein Therapeutics, by End Users USD Million (2023-2028)
  • Table 150. South Korea Plasma Protein Therapeutics, by Type USD Million (2023-2028)
  • Table 151. South Korea Plasma Protein Therapeutics, by Application USD Million (2023-2028)
  • Table 152. South Korea Plasma Protein Therapeutics, by End Users USD Million (2023-2028)
  • Table 153. Taiwan Plasma Protein Therapeutics, by Type USD Million (2023-2028)
  • Table 154. Taiwan Plasma Protein Therapeutics, by Application USD Million (2023-2028)
  • Table 155. Taiwan Plasma Protein Therapeutics, by End Users USD Million (2023-2028)
  • Table 156. Australia Plasma Protein Therapeutics, by Type USD Million (2023-2028)
  • Table 157. Australia Plasma Protein Therapeutics, by Application USD Million (2023-2028)
  • Table 158. Australia Plasma Protein Therapeutics, by End Users USD Million (2023-2028)
  • Table 159. Rest of Asia-Pacific Plasma Protein Therapeutics, by Type USD Million (2023-2028)
  • Table 160. Rest of Asia-Pacific Plasma Protein Therapeutics, by Application USD Million (2023-2028)
  • Table 161. Rest of Asia-Pacific Plasma Protein Therapeutics, by End Users USD Million (2023-2028)
  • Table 162. Europe Plasma Protein Therapeutics, by Country USD Million (2023-2028)
  • Table 163. Europe Plasma Protein Therapeutics, by Type USD Million (2023-2028)
  • Table 164. Europe Plasma Protein Therapeutics, by Application USD Million (2023-2028)
  • Table 165. Europe Plasma Protein Therapeutics, by End Users USD Million (2023-2028)
  • Table 166. Germany Plasma Protein Therapeutics, by Type USD Million (2023-2028)
  • Table 167. Germany Plasma Protein Therapeutics, by Application USD Million (2023-2028)
  • Table 168. Germany Plasma Protein Therapeutics, by End Users USD Million (2023-2028)
  • Table 169. France Plasma Protein Therapeutics, by Type USD Million (2023-2028)
  • Table 170. France Plasma Protein Therapeutics, by Application USD Million (2023-2028)
  • Table 171. France Plasma Protein Therapeutics, by End Users USD Million (2023-2028)
  • Table 172. Italy Plasma Protein Therapeutics, by Type USD Million (2023-2028)
  • Table 173. Italy Plasma Protein Therapeutics, by Application USD Million (2023-2028)
  • Table 174. Italy Plasma Protein Therapeutics, by End Users USD Million (2023-2028)
  • Table 175. United Kingdom Plasma Protein Therapeutics, by Type USD Million (2023-2028)
  • Table 176. United Kingdom Plasma Protein Therapeutics, by Application USD Million (2023-2028)
  • Table 177. United Kingdom Plasma Protein Therapeutics, by End Users USD Million (2023-2028)
  • Table 178. Netherlands Plasma Protein Therapeutics, by Type USD Million (2023-2028)
  • Table 179. Netherlands Plasma Protein Therapeutics, by Application USD Million (2023-2028)
  • Table 180. Netherlands Plasma Protein Therapeutics, by End Users USD Million (2023-2028)
  • Table 181. Rest of Europe Plasma Protein Therapeutics, by Type USD Million (2023-2028)
  • Table 182. Rest of Europe Plasma Protein Therapeutics, by Application USD Million (2023-2028)
  • Table 183. Rest of Europe Plasma Protein Therapeutics, by End Users USD Million (2023-2028)
  • Table 184. MEA Plasma Protein Therapeutics, by Country USD Million (2023-2028)
  • Table 185. MEA Plasma Protein Therapeutics, by Type USD Million (2023-2028)
  • Table 186. MEA Plasma Protein Therapeutics, by Application USD Million (2023-2028)
  • Table 187. MEA Plasma Protein Therapeutics, by End Users USD Million (2023-2028)
  • Table 188. Middle East Plasma Protein Therapeutics, by Type USD Million (2023-2028)
  • Table 189. Middle East Plasma Protein Therapeutics, by Application USD Million (2023-2028)
  • Table 190. Middle East Plasma Protein Therapeutics, by End Users USD Million (2023-2028)
  • Table 191. Africa Plasma Protein Therapeutics, by Type USD Million (2023-2028)
  • Table 192. Africa Plasma Protein Therapeutics, by Application USD Million (2023-2028)
  • Table 193. Africa Plasma Protein Therapeutics, by End Users USD Million (2023-2028)
  • Table 194. North America Plasma Protein Therapeutics, by Country USD Million (2023-2028)
  • Table 195. North America Plasma Protein Therapeutics, by Type USD Million (2023-2028)
  • Table 196. North America Plasma Protein Therapeutics, by Application USD Million (2023-2028)
  • Table 197. North America Plasma Protein Therapeutics, by End Users USD Million (2023-2028)
  • Table 198. United States Plasma Protein Therapeutics, by Type USD Million (2023-2028)
  • Table 199. United States Plasma Protein Therapeutics, by Application USD Million (2023-2028)
  • Table 200. United States Plasma Protein Therapeutics, by End Users USD Million (2023-2028)
  • Table 201. Canada Plasma Protein Therapeutics, by Type USD Million (2023-2028)
  • Table 202. Canada Plasma Protein Therapeutics, by Application USD Million (2023-2028)
  • Table 203. Canada Plasma Protein Therapeutics, by End Users USD Million (2023-2028)
  • Table 204. Mexico Plasma Protein Therapeutics, by Type USD Million (2023-2028)
  • Table 205. Mexico Plasma Protein Therapeutics, by Application USD Million (2023-2028)
  • Table 206. Mexico Plasma Protein Therapeutics, by End Users USD Million (2023-2028)
  • Table 207. Research Programs/Design for This Report
  • Table 208. Key Data Information from Secondary Sources
  • Table 209. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Plasma Protein Therapeutics: by Type USD Million (2017-2022)
  • Figure 5. Global Plasma Protein Therapeutics: by Application USD Million (2017-2022)
  • Figure 6. Global Plasma Protein Therapeutics: by End Users USD Million (2017-2022)
  • Figure 7. South America Plasma Protein Therapeutics Share (%), by Country
  • Figure 8. Asia Pacific Plasma Protein Therapeutics Share (%), by Country
  • Figure 9. Europe Plasma Protein Therapeutics Share (%), by Country
  • Figure 10. MEA Plasma Protein Therapeutics Share (%), by Country
  • Figure 11. North America Plasma Protein Therapeutics Share (%), by Country
  • Figure 12. Global Plasma Protein Therapeutics share by Players 2022 (%)
  • Figure 13. Global Plasma Protein Therapeutics share by Players (Top 3) 2022(%)
  • Figure 14. Global Plasma Protein Therapeutics share by Players (Top 5) 2022(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Octapharma AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 17. Octapharma AG (Switzerland) Revenue: by Geography 2022
  • Figure 18. CSL Limited (Australia) Revenue, Net Income and Gross profit
  • Figure 19. CSL Limited (Australia) Revenue: by Geography 2022
  • Figure 20. ADMA Biologics Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. ADMA Biologics Inc. (United States) Revenue: by Geography 2022
  • Figure 22. Taibang Biological Group Co. Ltd (China) Revenue, Net Income and Gross profit
  • Figure 23. Taibang Biological Group Co. Ltd (China) Revenue: by Geography 2022
  • Figure 24. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 25. Bayer AG (Germany) Revenue: by Geography 2022
  • Figure 26. Bio Products Laboratory Ltd. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 27. Bio Products Laboratory Ltd. (United Kingdom) Revenue: by Geography 2022
  • Figure 28. Takeda Pharmaceutical Company Limited (Japan) Revenue, Net Income and Gross profit
  • Figure 29. Takeda Pharmaceutical Company Limited (Japan) Revenue: by Geography 2022
  • Figure 30. Grifols (Spain) Revenue, Net Income and Gross profit
  • Figure 31. Grifols (Spain) Revenue: by Geography 2022
  • Figure 32. Kedrion (Italy) Revenue, Net Income and Gross profit
  • Figure 33. Kedrion (Italy) Revenue: by Geography 2022
  • Figure 34. Baxter International Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 35. Baxter International Inc. (United States) Revenue: by Geography 2022
  • Figure 36. Global Plasma Protein Therapeutics: by Type USD Million (2023-2028)
  • Figure 37. Global Plasma Protein Therapeutics: by Application USD Million (2023-2028)
  • Figure 38. Global Plasma Protein Therapeutics: by End Users USD Million (2023-2028)
  • Figure 39. South America Plasma Protein Therapeutics Share (%), by Country
  • Figure 40. Asia Pacific Plasma Protein Therapeutics Share (%), by Country
  • Figure 41. Europe Plasma Protein Therapeutics Share (%), by Country
  • Figure 42. MEA Plasma Protein Therapeutics Share (%), by Country
  • Figure 43. North America Plasma Protein Therapeutics Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Octapharma AG (Switzerland)
  • CSL Limited (Australia)
  • ADMA Biologics Inc. (United States)
  • Taibang Biological Group Co. Ltd (China)
  • Bayer AG (Germany)
  • Bio Products Laboratory Ltd. (United Kingdom)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Grifols (Spain)
  • Kedrion (Italy)
  • Baxter International Inc. (United States)
Select User Access Type

Key Highlights of Report


May 2023 244 Pages 74 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Plasma Protein Therapeutics Quantitative research analysis
Global Plasma Protein Therapeutics Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Plasma Protein Therapeutics market are Octapharma AG (Switzerland), CSL Limited (Australia), ADMA Biologics Inc. (United States), Taibang Biological Group Co. Ltd (China), Bayer AG (Germany), Bio Products Laboratory Ltd. (United Kingdom), Takeda Pharmaceutical Company Limited (Japan), Grifols (Spain), Kedrion (Italy) and Baxter International Inc. (United States), to name a few.
"Increased Research and Development Activities for Plasma Protein Therapeutics" is seen as one of major influencing trends for Plasma Protein Therapeutics Market during projected period 2022-2028.
Immunoglobulin segment in Global market to hold robust market share owing to "Increased Incidence of Autoimmune Diseases ".

Know More About Global Plasma Protein Therapeutics Report?

Have a Query? Click Here

Other Related Reports

Oral Anticoagulant Comprehensive Study by Type (Warfarin, Dabigatran, Rivaroxaban, Others), Application (Thromboembolic Disease, Disseminated Intravascular Coagulation, Cardiovascular Surgery, Others...
$ 3450
Primary Cells Comprehensive Study by Type (Human Primary Cells, Animal Primary Cells), Origin (Hematopoietic, Blood, Skin, Gastrointestinal, Hepatocytes, Renal, Skeleton & Muscles), End User (Researc...
$ 3350
Central Nervous System Comprehensive Study by Drugs (Biologic, Non- Biologic), Disease (Infectious Diseases, Neurodegenerative Diseases, Autoimmune and Inflammatory Diseases, Genetic Disorders, Cance...
$ 3450
Human Growth Hormone Comprehensive Study by Type (Recombinant Human Growth Hormone (rhGH), Human Growth Hormone (rhGH)), Application (Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stat...
$ 3450
Endobronchial Ultrasound Biopsy Comprehensive Study by Type (Biopsy Forceps, Cytology Brushes, Biopsy Needles, Transbronchial Aspiration Needles, Spray Catheters, Others), Application (Infection Diag...
$ 3650
Chamomile Oil Comprehensive Study by Type (High-Quality, Middle-Quality, Low-Quality), Application (Essential Oils, Other), Nature (Organic Chamomile Essential Oil, Conventional Chamomile Essential O...
$ 3450